Back Hepatitis C

Hepatitis C

Janssen Seeks Approval of Simeprevir + Sofosbuvir for HCV Genotype 1

Janssen Research & Development has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) requesting approval of its HCV protease inhibitor simeprevir (Olysio) for use with Gilead Sciences' HCV polymerase inhibitor sofosbuvir (Sovaldi) for certain treatment-naive and previously treated genotype 1 hepatitis C patients.

alt

CROI 2014 & EASL 2014: Treating Hepatitis B and C in HIV+ People Reduces Liver Disease

Effective antiviral treatment that suppresses hepatitis B virus (HBV) repliaction or eradicates hepatitis C virus (HCV) can lower the risk of developing advanced liver disease including cirrhosis, hepatocellular carcinoma, and decompensation in people with HIV and viral hepatitis coinfection, according to studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) and EASL International Liver Congress.

alt

EASL 2014: Idenix Hepatitis C Drugs Look Promising in Early Studies

Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX179) plus Janssen's HCV protease inhibitor simeprevir (Olysio) and ribavirin produced early sustained virological response rates of about 80% in a small study presented at the 49th EASL International Liver Congress last month in London. Another study showed that the company's HCV polymerase inhibitor candidate IDX21437 looks good in preclinical studies and is a potential once-daily partner for samatasvir in interferon-free regimens.

alt

May 19 is National Hepatitis Testing Day

May 19 is the third annual National Hepatitis Testing Day, an opportunity to raise awareness among healthcare providers and the public about screening for hepatitis B and C. According to the Centers for Disease Control and Prevention (CDC), among the approximately 3 million people with hepatitis C in the U.S., an estimated 75% do not know they are infected.

alt

Even Moderate Alcohol Use Raises Liver Fibrosis Risk in HIV/HCV Coinfected People

People with HIV alone or hepatitis C virus alone were more likely to have advanced liver fibrosis if they drank more alcohol, but people coinfected with both HIV and HCV had a greater risk of advanced fibrosis even with moderate or "non-hazardous" drinking, according to a report in the May 15 edition of Clinical Infectious Diseases.

alt

DDW 2014: New Hepatitis C Treatments Highlighted at Digestive Disease Week

Direct-acting antiviral agents for hepatitis C were a key theme of Digestive Disease Week 2014, taking place this week in Chicago. While the conference covers all aspects of gastroenterology and hepatology, new treatments that can cure more than 90% of chronic hepatitis C patients with few side effects in as little as 8 to 12 weeks are bringing about a revolution in the field.

alt

EASL 2014: Sofosbuvir + Ribavirin Is Safe and Effective for HCV Recurrence after Liver Transplant

An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C virus (HCV) recurrence, according to a poster presented at the 49thEASL International Liver Congress (EASL 2014) held recently in London.

alt

DDW 2014: Drinking More Coffee Is Associated with Less Liver Fibrosis

People with hepatitis C who drink more cups of coffee per day may have a lower likelihood of developing advanced liver fibrosis or cirrhosis -- but only if it contains caffeine, and tea does not appear to have a similar effect, according to a study presented at the Digestive Disease Week (DDW 2014) meeting this week in Chicago.

alt

EASL 2014: VX-135 + Daclatasvir Shows Modest Cure Rate in Phase 2 Study

Treatment with an interferon-free regimen of daclatasvir plus VX-135 for 12 weeks was safe and well-tolerated for genotype 1 chronic hepatitis C patients, but the sustained virological response rate of 83% for easier-to-treat patients did not stand up well to cure rates of 90% or higher seen with other similar combinations, according to a late-breaker poster presented at the 49thEASL International Liver Congress held recently in London.

alt